Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

Preetesh Jain, Hagop Kantarjian, Keyur P. Patel, Graciela Nogueras Gonzalez, Rajyalakshmi Luthra, Rashmi Kanagal Shamanna, Koji Sasaki, Elias Jabbour, Carlos Guillermo Romo, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Gautam Borthakur, Zeev Estrov, Farhad Ravandi, Susan O’Brien, Jorge Cortes

Blood (2016) 127 (10): 1269–1275.

https://doi.org/10.1182/blood-2015-10-674242

Published: 2016

Includes: Supplemental data

Journal Articles

Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities

Preetesh Jain, MBBS,MDDM,PhD, Hagop M. Kantarjian, MD, Raja Luthra, PhD, Graciela Nogueras Gonzalez, Elias Jabbour, Koji Sasaki, MD, Carlos Guillermo Romo, MD, Keyur P. Patel, MD PhD, Tapan Kadia, MD, Gautam Borthakur, MD, Zeev Estrov, MD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 598.

https://doi.org/10.1182/blood.V126.23.598.598

Published: 2015

Journal Articles

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Mary Joy Liboon, Evguenia Gachimova, Tapan M. Kadia, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 4019.

https://doi.org/10.1182/blood.V122.21.4019.4019

Published: 2013

Journal Articles

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Rajyalakshmi Luthra, PhD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Farhad Ravandi, MBBS, Susan M. O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2727.

https://doi.org/10.1182/blood.V122.21.2727.2727

Published: 2013

Journal Articles

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Mona Lisa Alattar, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Carlos Guillermo Romo, MD, Sara E Dellasala, RN, Sherry Pierce, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2728.

https://doi.org/10.1182/blood.V122.21.2728.2728

Published: 2013

Journal Articles

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Preetesh Jain, Hagop Kantarjian, Aziz Nazha, Susan O’Brien, Elias Jabbour, Carlos Guillermo Romo, Sherry Pierce, Marylou Cardenas-Turanzas, Srdan Verstovsek, Gautam Borthakur, Farhad Ravandi, Alfonso Quintás-Cardama, Jorge Cortes

Blood (2013) 121 (24): 4867–4874.

https://doi.org/10.1182/blood-2013-03-490128

Published: 2013

Includes: Supplemental data

NARROW

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Email alerts

ASH Publications

American Society of Hematology

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only